RedHill Biopharma is a biopharmaceutical company with a diversified, balanced R&D pipeline and late-stage assets focusing on gastrointestinal (GI) diseases and inflammation. The three most advanced Phase III-stage products have been significantly de-risked, target areas with high unmet need and may deliver four key readouts with the next 18 months. We initiate coverage of RedHill with a valuation of NIS1.21-1.29bn or NIS9.5-10.1/share.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs